Last reviewed · How we verify
Repeat IV dose of GSK2862277 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Repeat IV dose of GSK2862277 (Repeat IV dose of GSK2862277) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Repeat IV dose of GSK2862277 TARGET | Repeat IV dose of GSK2862277 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Repeat IV dose of GSK2862277 CI watch — RSS
- Repeat IV dose of GSK2862277 CI watch — Atom
- Repeat IV dose of GSK2862277 CI watch — JSON
- Repeat IV dose of GSK2862277 alone — RSS
Cite this brief
Drug Landscape (2026). Repeat IV dose of GSK2862277 — Competitive Intelligence Brief. https://druglandscape.com/ci/repeat-iv-dose-of-gsk2862277. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab